ADR,SEQ,PT,HLT,HLGT,SOC_ABBREV,FATAL_YN
1,1,Eczema,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
1,2,Skin irritation,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
2,1,Application site reaction,Application site reactions,Administration site reactions,Genrl,N
2,2,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
3,1,Scrotal oedema,Scrotal disorders NEC,Penile and scrotal disorders (excl infections and inflammations),Repro,N
3,2,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
4,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4,2,Skin discolouration,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
5,1,Therapeutic response unexpected,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
6,1,Hair colour changes,Pilar disorders NEC,Skin appendage conditions,Skin,N
7,1,Skin striae,Skin hypoplasias and atrophies,Cornification and dystrophic skin disorders,Skin,N
8,1,Application site reaction,Application site reactions,Administration site reactions,Genrl,N
8,2,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
9,1,Hair colour changes,Pilar disorders NEC,Skin appendage conditions,Skin,N
10,1,Skin discolouration,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
11,1,Asthma,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
12,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
